Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q3 2023 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2022 Net Income-$7.29M-$7.29MN/M vs Q3 2022 EPS Diluted-$11.07-$11.07N/M vs Q3 2022 Operating Income-$6,169,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,671,000N/M ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end